Mylan, Sunovion Reach Terms In Xopenex Patent Fight

Law360, New York (May 29, 2012, 5:50 PM EDT) -- Mylan Inc. said Tuesday it had settled a patent fight with Sunovion Pharmaceuticals Inc. over the asthma drug Xopenex, in a deal that will allow Mylan to continue selling its own version of the drug and release it from paying an $18 million damages award.

The settlement ends a protracted fight between the companies that started in 2006, when Sunovion alleged that Mylan had willfully infringed five patents for the medication. In 2008, Mylan sued Sunovion, seeking a declaratory judgment labeling a separate patent covering the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.